Financial Overview of Fulgent Genetics

Fulgent Genetics is a technology-based company with two main business segments - a laboratory services business and a therapeutic development business. The company recently completed the acquisition of Bako Diagnostics and StrataDx, which provide dermatopathology, podiatric pathology, and molecular diagnostic services and therapeutic products.

Revenue and Profit Trends

Fulgent’s total revenue decreased by 3% from $73.5 million in the first quarter of 2025 to $71.1 million in the first quarter of 2026. This was driven by a 9% decline in precision diagnostics revenue and a 1% decline in anatomic pathology revenue, partially offset by a 41% increase in BioPharma services revenue.

The decrease in precision diagnostics revenue was due to declining sales to Fulgent’s largest customer, as this customer begins to perform more tests internally. Anatomic pathology services remained relatively consistent, with the slight decrease due to timing of claims processing. The increase in BioPharma services revenue was from the timing of service projects, though this revenue is expected to remain variable.

Fulgent’s cost of revenue increased by 10% from $45.1 million to $49.6 million, primarily due to higher personnel expenses, shipping costs, reagent and supply costs, and depreciation. This caused gross profit to decrease by 24%, from $28.3 million to $21.5 million, and gross margin to decline from 39% to 30%.

Strengths and Weaknesses

A key strength of Fulgent is its flexible and scalable testing platform that allows it to offer a broad menu of tests. This has provided a competitive advantage in the market. However, the company faces risks from customer concentration, with its largest customer accounting for 15% of revenue in Q1 2026, down from 24% in Q1 2025 as this customer brings more testing in-house.

Another weakness is the variability in BioPharma services revenue due to the long sales cycle and fluctuations in project timing. The company will need to focus on diversifying its customer base and revenue streams to reduce this volatility.

The Bako Acquisition is a major transaction that brings both opportunities and risks. While it expands Fulgent’s service offerings, the integration of these operations could present challenges and higher than anticipated costs.

Outlook and Future Prospects

Looking ahead, Fulgent expects the impact of the Bako Acquisition to be more fully reflected in its results starting in the second quarter of 2026 and beyond. The company will focus on developing existing customers, increasing its customer base, and successfully integrating the acquired businesses to offset the declining revenue from its largest customer.

Research and development expenses are expected to continue increasing as Fulgent progresses its therapeutic candidates through clinical trials. The company’s strong cash position of $604.7 million as of March 31, 2026 should provide the resources to fund these R&D efforts, as well as potential future acquisitions and stock repurchases.

Overall, Fulgent faces both opportunities and challenges in the coming periods. Its ability to diversify its customer base, integrate acquisitions effectively, and advance its therapeutic pipeline will be key to its future performance and growth.

Financial Summary

The key financial highlights from Fulgent’s Q1 2026 results are:

Revenue:

• Total revenue decreased 3% to $71.1 million
• Precision diagnostics revenue declined 9% to $40.2 million
• Anatomic pathology revenue declined 1% to $25.1 million
• BioPharma services revenue increased 41% to $5.8 million

Profitability:

• Gross profit decreased 24% to $21.5 million
• Gross margin declined from 39% to 30%
• Operating loss increased 75% to $34.6 million
• Net loss attributable to Fulgent increased 115% to $24.8 million

Cash and Liquidity:

• Cash, cash equivalents, restricted cash, and marketable securities totaled $604.7 million as of March 31, 2026
• Cash provided by operating activities was $7.1 million in Q1 2026, compared to $4.4 million used in Q1 2025
• $99.6 million remained available under the $250 million stock repurchase program as of March 31, 2026

In summary, Fulgent Genetics faced revenue and profitability challenges in the first quarter of 2026, driven by declines in its precision diagnostics and anatomic pathology businesses, as well as increased costs related to the Bako Acquisition. However, the company maintains a strong cash position to fund its operations, R&D efforts, and strategic initiatives going forward. Successful integration of the Bako business and diversification of its customer base will be key to Fulgent’s future performance.